05/27/2025
The Inclusion Body Myositis Disease Registry at Yale is a collaborative initiative between the Yale School of Public Health, medical professionals and proactive people with IBM.
Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from The Inclusion Body Myositis Registry at Yale, 60 College Street, 3rd Floor (HPM), P. O. Box 208034, New Haven, CT.
60 College Street, 3rd Floor (HPM), P. O. Box 208034
New Haven, CT
06520
Be the first to know and let us send you an email when The Inclusion Body Myositis Registry at Yale posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
We are a team of researchers and physicians dedicated to helping IBM patients and their families by providing informational and practical tools to better understand the disease, as well as establishing platforms to support clinical and scientific IBM research.
In 2011, Dr. Martin Shubik (left, in the picture above), a retired Yale professor and an IBM patient himself, provided the Yale School of Public Health with the funds to begin collecting data on this rare disease. A project that began in 2012 with a survey to collect and study clinical profiles from IBM patients across North America, the Yale Registry is now the largest systematic categorization of IBM.
In addition to showcasing survey findings, the IBM Registry at Yale (www.ibm.yale.edu) is host to a number of other resources. The most recent addition, and part of an exciting new project, is the IBM Personalized Index Calculator, designed to help people with IBM track the progression of their disease. We hope that the data we collect will help patients and doctors better understand how IBM affects different people over time.
As we continue to grow, our mission remains to help and support all involved with IBM. Please do not hesitate to reach out to us. We invite you to join us in this collective effort to learn more and to hopefully one day find a cure for IBM.